Literature DB >> 8464733

Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein.

C Vink1, A M Oude Groeneger, R H Plasterk.   

Abstract

The integrase (IN) protein of the human immunodeficiency virus (HIV) is required for specific cleavage of the viral DNA termini, and subsequent integration of the viral DNA into target DNA. To identify the various domains of the IN protein we generated a series of IN deletion mutants as fusions to maltose-binding protein (MBP). The deletion mutants were tested for their ability to bind DNA, to mediate site-specific cleavage of the viral DNA ends, and to carry out integration and disintegration reactions. We found that the DNA-binding region resides between amino acids 200 and 270 of the 288-residues HIV-1 IN protein. The catalytic domain of the protein was mapped between amino acids 50 and 194. For the specific activities of IN, cleavage of the viral DNA and integration, both the DNA-binding domain and the conserved amino-terminal region of IN are required. These regions are dispensable however, for disintegration activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464733      PMCID: PMC309327          DOI: 10.1093/nar/21.6.1419

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  29 in total

Review 1.  Integration of retroviral DNA.

Authors:  P O Brown
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer.

Authors:  A Engelman; K Mizuuchi; R Craigie
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

3.  Defining nucleic acid-binding properties of avian retrovirus integrase by deletion analysis.

Authors:  S R Mumm; D P Grandgenett
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

4.  Retroviral integrase domains: DNA binding and the recognition of LTR sequences.

Authors:  E Khan; J P Mack; R A Katz; J Kulkosky; A M Skalka
Journal:  Nucleic Acids Res       Date:  1991-02-25       Impact factor: 16.971

5.  Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage.

Authors:  C Vink; D C van Gent; Y Elgersma; R H Plasterk
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Functional similarities between retroviruses and the IS3 family of bacterial insertion sequences?

Authors:  O Fayet; P Ramond; P Polard; M F Prère; M Chandler
Journal:  Mol Microbiol       Date:  1990-10       Impact factor: 3.501

7.  The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.

Authors:  R A Katz; G Merkel; J Kulkosky; J Leis; A M Skalka
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

8.  Site-specific hydrolysis and alcoholysis of human immunodeficiency virus DNA termini mediated by the viral integrase protein.

Authors:  C Vink; E Yeheskiely; G A van der Marel; J H van Boom; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1991-12-25       Impact factor: 16.971

9.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

10.  Substrate specificity of recombinant human immunodeficiency virus integrase protein.

Authors:  R L LaFemina; P L Callahan; M G Cordingley
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more
  105 in total

Review 1.  Retroviral DNA integration.

Authors:  P Hindmarsh; J Leis
Journal:  Microbiol Mol Biol Rev       Date:  1999-12       Impact factor: 11.056

2.  Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase.

Authors:  T Ishikawa; N Okui; N Kobayashi; R Sakuma; T Kitamura; Y Kitamura
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases.

Authors:  Iris Oz; Orna Avidan; Amnon Hizi
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

4.  Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein.

Authors:  J Y Wang; H Ling; W Yang; R Craigie
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

5.  Molecular dynamics studies on the HIV-1 integrase catalytic domain.

Authors:  R D Lins; J M Briggs; T P Straatsma; H A Carlson; J Greenwald; S Choe; J A McCammon
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

Review 6.  Allosteric inhibitor development targeting HIV-1 integrase.

Authors:  Laith Q Al-Mawsawi; Nouri Neamati
Journal:  ChemMedChem       Date:  2011-01-12       Impact factor: 3.466

7.  Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration.

Authors:  M L Holmes-Son; S A Chow
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Juxtaposition of two viral DNA ends in a bimolecular disintegration reaction mediated by multimers of human immunodeficiency virus type 1 or murine leukemia virus integrase.

Authors:  S A Chow; P O Brown
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Differential multimerization of Moloney murine leukemia virus integrase purified under nondenaturing conditions.

Authors:  Rodrigo A Villanueva; Colleen B Jonsson; Jennifer Jones; Millie M Georgiadis; Monica J Roth
Journal:  Virology       Date:  2003-11-10       Impact factor: 3.616

10.  Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues.

Authors:  P M Cannon; W Wilson; E Byles; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.